Celtic Pharma And Russia's Rusnano Set Up Pro Bono Bio, A New Firm With Philanthropic Objectives
This article was originally published in PharmAsia News
Executive Summary
A new pharmaceutical company, Pro Bono Bio, has been set up by private equity firm Celtic Pharma Holdings in London and a Russian government investment vehicle, Rusnano, and has launched its first product, an analgesic gel, Flexiseq, which works by sequestering arachidonic acid and is approved as a medical device in Europe
You may also be interested in...
Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 Million
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).